Cargando…

Measurement of bone turnover in prostate cancer patients receiving intermittent androgen suppression therapy

PURPOSE: Reports on clinical measurements of bone mineral density (BMD) in prostate cancer patients undergoing intermittent androgen suppression therapy (IAS) that allows for hormonal recovery between treatment cycles indicate decreased osteoporosis compared to continuous androgen suppression therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Theyer, Gerhard, Holub, Stefan, Olszewski, Ulrike, Hamilton, Gerhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818886/ https://www.ncbi.nlm.nih.gov/pubmed/24198623 http://dx.doi.org/10.2147/OAJU.S13046

Ejemplares similares

Type I Collagen Synthesis Marker Procollagen I N-Terminal Peptide (PINP) in Prostate Cancer Patients Undergoing Intermittent Androgen Suppression
por: Hamilton, Gerhard, et al.
Publicado: (2011)

Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy.
por: Theyer, G., et al.
Publicado: (1997)

Intermittent chemotherapy in metastatic androgen-independent prostate cancer
por: Beer, T M, et al.
Publicado: (2003)

AB03. Intermittent androgen suppression: current status
por: Goldenberg, Larry
Publicado: (2014)

Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots
por: Abrahamsson, Per-Anders
Publicado: (2017)

Concerted Action of Androgens and Mechanical Strain Shifts Bone Metabolism from High Turnover into an Osteoanabolic Mode
por: Liegibel, Ute M., et al.
Publicado: (2002)

Autophagy in Prostate Cancer and Androgen Suppression Therapy
por: Ziparo, Elio, et al.
Publicado: (2013)

Intermittent Androgen Suppression: Estimating Parameters for Individual Patients Based on Initial PSA Data in Response to Androgen Deprivation Therapy
por: Hirata, Yoshito, et al.
Publicado: (2015)

Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer
por: Beer, T M, et al.
Publicado: (2004)

Benefits of intermittent/continuous androgen deprivation in patients with advanced prostate cancer
por: MURESANU, HORIA
Publicado: (2016)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Dependence of Relative Expression of NTR1 and EGFR on Cell Density and Extracellular pH in Human Pancreatic Cancer Cell Lines
por: Olszewski-Hamilton, Ulrike, et al.
Publicado: (2011)

CD99/MIC2 Constitutes a Differentiation Antigen of a Human Osteoblast Cell Line
por: Hamilton, Gerhard, et al.
Publicado: (2011)

Physical exercise for bone health in men with prostate cancer receiving androgen deprivation therapy: a systematic review
por: Bressi, Barbara, et al.
Publicado: (2020)

Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation
por: Brady-Nicholls, Renee, et al.
Publicado: (2020)

Low Bone Turnover and Low BMD in Down Syndrome: Effect of Intermittent PTH Treatment
por: Fowler, Tristan W., et al.
Publicado: (2012)

Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy
por: Lorenzo, Giuseppe Di, et al.
Publicado: (2022)

Can prophylactic breast irradiation contribute to cardiac toxicity in patients with prostate cancer receiving androgen suppressing drugs?
por: Nieder, Carsten, et al.
Publicado: (2008)

Pathophysiology of Bone Loss in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy and Lifestyle Modifications for the Management of Bone Health: A Comprehensive Review
por: Kim, Tae Jin, et al.
Publicado: (2020)

Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach
por: Bonfill, Xavier, et al.
Publicado: (2018)

A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy
por: Lee, C Ellen, et al.
Publicado: (2012)

Decreased Risk of Renal Calculi in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
por: Lin, Chien-Yu, et al.
Publicado: (2020)

Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan
por: Liao, Kuang-Ming, et al.
Publicado: (2019)

Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
por: Shore, Richard, et al.
Publicado: (2021)

PDZRN4 suppresses tumorigenesis and androgen therapy-resistance in prostate cancer
por: Jin, Peng, et al.
Publicado: (2022)

Suppressive Role of Androgen/Androgen Receptor Signaling via Chemokines on Prostate Cancer Cells
por: Izumi, Kouji, et al.
Publicado: (2019)

Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy
por: Maru, Shintaro, et al.
Publicado: (2018)

Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancer
por: Niraula, Saroj, et al.
Publicado: (2017)

Feasibility and Safety of Physical Exercise to Preserve Bone Health in Men With Prostate Cancer Receiving Androgen Deprivation Therapy: A Systematic Review
por: Cagliari, Maribel, et al.
Publicado: (2021)

Markers of bone turnover for the management of patients with bone metastases from prostate cancer
por: Garnero, P, et al.
Publicado: (2000)

Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder
por: Chung, Shiu-Dong, et al.
Publicado: (2017)

Statin Use and Survival Among Men Receiving Androgen-Ablative Therapies for Advanced Prostate Cancer: A Systematic Review and Meta-analysis
por: Jayalath, Viranda H., et al.
Publicado: (2022)

Implementing and Evaluating the Impact of BoneRx: A Healthy Bone Prescription for Men with Prostate Cancer Initiating Androgen Deprivation Therapy
por: Jones, Jennifer M., et al.
Publicado: (2022)

Persistent Testosterone Suppression After Cessation of Androgen Deprivation Therapy for Prostate Cancer
por: Delgado, Jessica, et al.
Publicado: (2022)

Three cases of nonmetastatic prostate cancer treated successfully with primary intermittent androgen deprivation therapy over 10 years
por: Shida, Yohei, et al.
Publicado: (2017)

Long Term Progression-Free Survival in a Patient with Locally Advanced Prostate Cancer under Low Dose Intermittent Androgen Deprivation Therapy with Bicalutamide Only
por: Latz, Stefan, et al.
Publicado: (2015)

AB37. The combination of I brachytherapy with intermittent androgen deprivation in treating locally advanced prostate cancer
por: Huang, Yi
Publicado: (2014)

Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling
por: Hirata, Yoshito, et al.
Publicado: (2018)

Comparison of the effects of the oral anticancer platinum(IV) complexes oxoplatin and metabolite cis-diammine-tetrachlorido-platinum(IV) on global gene expression of NCI-H526 cells
por: Olszewski, Ulrike, et al.
Publicado: (2011)

HOXB13 is co-localized with androgen receptor to suppress androgen-stimulated prostate-specific antigen expression
por: Kim, Sin Do, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_gigghbkvvpvm1g4lmuo65jbfad